5/29/2020 1:08:44 AM
Argenx Reports Full Exercise Of Underwriters' Option To Purchase Addl ADSs
5/28/2020 12:25:42 AM
Argenx Announces Pricing Of $750 Mln Of Global Offering Of Ordinary Shares
5/26/2020 1:09:50 AM
Argenx Reports Positive Topline Data From Pivotal ADAPT Trial Of Efgartigimod
2/4/2019 1:02:11 AM
Argenx, Halozyme Therapeutics Enter Global Collaboration And License Agreement For ENHANZE Technology
12/17/2018 2:31:47 AM
Forbion Portfolio Company Staten Biotechnology Enters Into Collaboration With Novo Nordisk
12/4/2018 7:49:18 AM
Wedbush Reiterates argenx SE (ARGX) At Outperform With $131 Up From $130 Price Target
12/3/2018 1:02:31 AM
Argenx Enters Global Collaboration And License Agreement With Cilag GmbH International For Cusatuzumab (ARGX-110)
12/3/2018 1:01:46 AM
Argenx Provides Detailed Data From Phase 2 Clinical Trial Of Efgartigimod In Immune Thrombocytopenia
11/5/2018 6:53:28 AM
Wedbush Reiterates argenx SE (ARGX) At Outperform With $130 Up From $125 Price Target
9/20/2018 6:43:14 AM
Wedbush Reiterates argenx SE (ARGX) At Outperform With $125 Up From $121 Price Target
9/18/2018 6:38:23 AM
Wedbush Reiterates argenx SE (ARGX) At Outperform With $121 Up From $114 Price Target
8/22/2018 2:04:24 AM
Argenx Announces Exercise Of Its Exclusive License Option To Develop And Commercialize ARGX-115
6/28/2018 1:03:07 AM
Argenx Announces Achievement Of Second Of Two Preclinical Milestones Towards IND Filing For ARGX-115